Amy Witman
Internal Medicine · San Diego, CANPI 1679670327
Payments from drug & device makers
Across 120 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$877
- Lilly USA, LLC$323
- AbbVie$306
- AMAG Pharmaceuticals, Inc.$122
- Novo Nordisk$87
- Novartis$73
- plus $757 from 23 others
What the payments were for
- Food & beverage$2,51899%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 44 | $877 |
| Lilly USA, LLC | 9 | $323 |
| AbbVie(2 entities) | 16 | $306 |
| AMAG Pharmaceuticals, Inc. | 1 | $122 |
| Novo Nordisk | 4 | $87 |
| Novartis | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $65 |
| AstraZeneca | 4 | $62 |
| Therapeuticsmd, Inc. | 4 | $58 |
| GSK | 3 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $49 |
| Boehringer Ingelheim | 2 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Pfizer | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Merck | 2 | $35 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Abbott | 1 | $26 |
| Bayer | 1 | $25 |
| Duchesnay USA Incorporated | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $23 |
| Nalpropion Pharmaceuticals LLC | 1 | $22 |
| Exact Sciences | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Endogastric Solutions, Inc | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,545 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 31 | $27,022 |
| MounjaroTirzepatide | 12 | $24,768 |
| JardianceEmpagliflozin | 19 | $22,195 |
| EliquisApixaban | 13 | $19,101 |
| Nurtec OdtRimegepant Sulfate | 18 | $16,995 |
| OzempicSemaglutide | 14 | $15,761 |
| JanuviaSitagliptin Phosphate | 14 | $13,684 |
| FarxigaDapagliflozin Propanediol | 11 | $13,359 |
| XareltoRivaroxaban | 16 | $11,950 |
| Praluent PenAlirocumab | 13 | $11,917 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $7,921 |
| SynthroidLevothyroxine Sodium | 30 | $3,501 |
| Estradiol | 30 | $3,416 |
| Dexlansoprazole DrDexlansoprazole | 11 | $2,999 |
| Ezetimibe | 37 | $1,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $38 | $36,09631 claims |
| Lilly USA, LLCMounjaro | $323 | $24,76812 claims |
| Boehringer IngelheimJardiance | $47 | $22,19519 claims |
| Novo NordiskOzempic | $87 | $15,76114 claims |
| MerckJanuvia | $35 | $13,68414 claims |
| AstraZenecaFarxiga | $62 | $13,35911 claims |
| Johnson & JohnsonXarelto | $16 | $11,95016 claims |
| GSKBreo Ellipta | $51 | $7,92113 claims |
| AbbVieSynthroid | $306 | $3,50130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Diego
- Donald BrandonSan Diego$34M
- Elaine WatkinsSan Diego$11.3M
- James ChenSan Diego$2.9M
- Rita StarrittSan Diego$2.6M
- Hatim HusainSan Diego$2.6M
- Gary FiresteinSan Diego$2.6M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.